Parasite | Eso | Sto | Cancer | ESD
[Esophageal candidasis. ½Äµµ ĵð´ÙÁõ] - ðû
1) ºÐ·ù
2) ¿ªÇÐ
3) Ä¡·á
4) ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ Asymptomatic esophageal candidiasis
5) ĵð´Ù °¨¿° À§±Ë¾ç°ú À§¾Ï Candida-infected gastric ulcer and cancer
6) FAQ
7) References
2013³â 11¿ù 18ÀÏ SGEA¿¡¼ »ï¼º¼¿ïº´¿ø ³ªÀ±ÁÖ ¼±»ý´Ô²²¼ ½Äµµ ĵð´ÙÁõ ½Äµµ¿° ºÐ·ù¸¦ ¼³¸íÇØ Áּ̽À´Ï´Ù. °¨»çÇÕ´Ï´Ù.
ĵð´Ù ½Äµµ¿°ÀÇ À§ÇèÀÎÀÚ´Â ¾Æ·¡¿Í °°½À´Ï´Ù.
½Äµµ¿°À» ¿øÀκ°·Î ºÐ·ùÇÏ¿© Áõ»ó ¾ç»óÀ» ºñ±³ÇÑ ¾Æ·¡ tableÀ» º¸¸é ½Äµµ ĵð´ÙÁõÀº ¹«Áõ»óÀÎ °æ¿ì°¡ ¸¹½À´Ï´Ù.
À§ °¡À̵å¶óÀÎÀº ÁÖ·Î immunocompromised patients (´ëºÎºÐ AIDS) ¸¦ ´ë»óÀ¸·Î ÇÑ ¿¬±¸ °á°ú¸¦ ¹ÙÅÁÀ¸·Î ÀÛ¼ºµÈ °Í °°Àºµ¥, ÇÑ ¸¶µð·Î Ä¡·á°¡ ³Ê¹« ¼¼´Ù°í »ý°¢µË´Ï´Ù. ¸é¿ª Á¤»óÀÎ °æ¿ì´Â º¸Åë fluconazole 50 mg bid for 7-10 days Á¤µµ·Î È£ÀüµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.
Âü°í·Î ¸é¿ª±â´ÉÀÌ Á¤»óÀÎ ¹«Áõ»ó °æÁõ candidiasis´Â oral hygiene Á¤µµ °Á¶ÇÏ°í Åõ¾àÀ» ÇÒ ÇÊ¿ä´Â ¾øÀ» °Í °°½À´Ï´Ù.
4-1) ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ ³»½Ã°æ ¼Ò°ß
¹«Áõ»ó ½Äµµ ĵð´ÙÁõ + ¹«Áõ»ó ½Äµµ SMT
TNM ÆóÁúȯ ȯÀÚÀÇ ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ
À̰͵µ ĵð´ÙÁõÀ̶ó°í ÇÒ ¼ö ÀÖÀ»±î? Á¶Á÷°Ë»ç·Î È®ÀεDZâ´Â ÇÏ¿´À½.
Hiatal hernia°¡ Àִ ȯÀÚÀÇ ½Äµµ¿¡¼ ÇϾá Á¡ °°Àº º´¼ÒµéÀÌ ¹ß°ßµÇ¾úÀ¸¸ç Á¶Á÷°Ë»ç·Î candidiasis°¡ È®ÀεǾú½À´Ï´Ù. Àú¸¸ÀÇ °æÇèÀÎÁö´Â ¸ð¸£°ÚÀ¸³ª ¿ª·ù¼º ½Äµµ¿°ÀÌ Àִ ȯÀÚ¿¡¼ ½Äµµ candidiasis°¡ ÈçÇÑ °Í °°½À´Ï´Ù. ¿À´ÃÀÇ Áõ·Ê¿¡¼´Â º° ´Ù¸¥ Áõ¼¼°¡ ¾ø¾úÁö¸¸ asymptomatic reflux´Â ¸¹Àº °ÍÀ¸·Î ÃßÁ¤µÇ´Â »óȲÀÔ´Ï´Ù.
Pd ¼Ò·® »ç¿ëÀåÀÇ ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ
±â°üÁö õ½ÄÀ¸·Î inhaler¸¦ »ç¿ëÇϴ ȯÀÚ¿¡¼ ¹ß°ßµÈ ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ. FluconazoleÀ» ó¹æÇÒ ¼öµµ ÀÖ°í ¾È ÇÒ ¼öµµ ÀÖ°ÚÀ¸³ª... Àû¾îµµ inhaler »ç¿ë¹ý Àç±³À°Àº ÇÊ¿äÇÏ´Ù°í º¾´Ï´Ù.
³»½Ã°æ ¼Ò°ßÀº ºñ½ÁÇѵ¥ 2³â Àü¿¡´Â Á¶Á÷°Ë»ç¿¡¼ ¾È ³ª¿Ô°í À̹ø¿¡´Â Á¶Á÷°Ë»ç·Î È®ÀεÊ.
À۳⠰ÇÁø¿¡¼ candidiasis°¡ ³ª¿Í¼ Ä¡·áÇߴµ¥ ±Ý³â¿¡µµ ¶Ç candidiasis°¡ ³ª¿Â °æ¿ì
ESD ¶§¿¡´Â ¾ø´ø Candida°¡ 2´Þ ÈÄ ÃßÀû³»½Ã°æ¿¡¼ ¹ß°ßµÊ. PPI Å¿Àϱî? Àü¿¡ ³õÄ£°É±î?
4-2) ¹«Áõ»ó ĵð´ÙÁõÀÇ À§ÇèÀÎÀÚ¿Í ÇÔ²² °üÂûµÇ´Â ³»½Ã°æ ¼Ò°ß
Prevalence and risk factors of esophageal candidiasis in healthy individuals: a single center experience in Korea. (link)
PURPOSE: Esophageal candidiasis (EC) is the most frequent opportunistic fungal infection in immunocompromised host. However, we have found EC in healthy individuals through esophagogastroduodenoscopy (EGD). The aim of this study was to determine the prevalence and risk factors for EC in healthy individuals.
MATERIALS AND METHODS: We retrospectively reviewed the medical records of 281 patients who had been incidentally diagnosed with EC. We also conducted age and sex matched case control study to identify the risk factor for EC.
RESULTS: The prevalence of EC was 0.32% (281/88125). The most common coexisting EGD finding was reflux esophagitis (49/281, 17.4%). An antifungal agent was prescribed in about half of EC, 139 cases (49.5%). Follow-up EGD was undertaken in 83 cases (29.5%) and 20 cases of candidiasis was persistently found. Case control study revealed EC were more often found in user of antibiotics (p=0.015), corticosteroids (p=0.002) and herb medication (p=0.006) as well as heavy drinking (p<0.001).
CONCLUSION: The prevalence of EC was 0.32% (281/88125) in Korea. Use of antibiotics, corticosteroids and herb as well as heavy drinking were significant risk factors for EC in healthy individuals.
¿¬±¸ÀÚµéÀÇ Discussion¿¡ Èï¹Ì·Î¿î ºÎºÐÀÌ ÀÖ¾ú½À´Ï´Ù. "In immunocompetent hosts, chronic alcohol consumption and long-standing gastroesophageal reflux may increase the risk of transmural invasive Candida infection and esophageal perforation."
Àú´Â À§½Äµµ¿ª·ù°¡ "¹«Áõ»ó ½ÄµµÄµð´ÙÁõ"ÀÇ Áß¿äÇÑ predisposing factorÀÏ °ÍÀ¸·Î ¹Ï½À´Ï´Ù. µ¿±¹´ë ¿¬±¸ÆÀÀÇ ÀÚ·á¿¡¼µµ ¿ª·ù¼º ½Äµµ¿°ÀÌ ¹«·Á 17.4%³ª µ¿¹ÝµÇ¾î ÀÖ¾ú½À´Ï´Ù. Nonerosive reflux diseaseµµ ¸¹´Ù´Â °ÍÀ» »ý°¢Çغ¸¸é À§½Äµµ¿ª·ù°¡ Áß¿äÇÑ ¿äÀÎÀÏ °Í °°½À´Ï´Ù. °ú°ÅÀÇ ¹®Ç庸°í¿¡¼µµ À§½Äµµ¿ª·ùÁúȯ°ú ½Äµµ ĵð´ÙÁõÀÇ ¿¬°ü¼ºÀÌ ¾ð±ÞµÈ °æ¿ì°¡ ÀÖ½À´Ï´Ù (World J Pediatr. 2009)
4-3) Áõ·Ê - 6³â °£ ¸Å³â ³»½Ã°æ °Ë»ç¸¦ ¹Þ¾Ò´ø ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ ¼öÁøÀÚ (ȯÀÚÀÎÁö ¸íÈ®ÇÏÁö ¾Ê¾Æ¼ ¼öÁøÀÚ¶ó°í Ç¥ÇöÇØ º¸¾Ò½À´Ï´Ù.) - 2016³â 5¿ù 19ÀÏ ¸ñ¿ä³»½Ã°æÁý´ãȸ
°ÇÁø¿¡¼ ¸Å³â Candidasis°¡ ³ª¿Í ÀÇ·ÚµÇ¾î ¸Å³â fluconazoleÀ» µå·È´Ù°í ÇÕ´Ï´Ù. ±×·±µ¥ ¸î ³â ¿¬¼Ó ³ª¿À´Ù°¡ ¾î´À ÇغÎÅÍ ³ª¿ÀÁö ¾Ê¾Ò½À´Ï´Ù. ¾îÂîµÈ ¿µ¹®ÀÎÁö ¾Ë ¼ö ¾ø½À´Ï´Ù. ¸é¿ªÀúÇÏȯÀÚ°¡ ¾Æ´Ñ °æ¿ì ¹«Áõ»ó ½Äµµ ĵð´ÙÁõÀº Áß¿äÇÑ Áúº´À¸·Î ÁøÇàÇÏÁö ¾Ê´Â self-limited disease°¡ ºÐ¸íÇÑ °Í °°½À´Ï´Ù. °Ë»çÇÏ°í °á°úÆǵ¶À» ÇÏ´Â Àǻ簡 Àß ¼³¸íÇÏ°í ÀÇ·ÚÇÏÁö ¾ÊÀ¸¸é Ä¡·áÇÏÁö ¾Ê°í °æ°ú°üÂûÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÏ´Ü È¯ÀÚ¸¦ ÀÇ·Ú¹ÞÀ¸¸é Ä¡·áÇÏÁö ¾Ê±â´Â ¾î·Æ½À´Ï´Ù.
°ü·ÃÇÏ¿© ÃÖ±Ù °Ç±¹´ëÇб³ º´¿ø¿¡¼ ¹«Áõ»ó ½Äµµ ĵð´ÙÁõÀÇ ÀÚ¿¬ °æ°ú¿¡ ´ëÇÑ ³í¹®À» ¹ßÇ¥ÇÑ ¹Ù ÀÖ½À´Ï´Ù (Lee SP. Scand J Gastroenterol 2015). Ä¡·á°¡ ÇÊ¿äÇÏÁö ¾Ê´Ù´Â °á·ÐÀÔ´Ï´Ù.
MATERIALS AND METHODS: A total of 49,497 subjects who underwent a health inspection that included upper endoscopy were enrolled. We retrospectively reviewed the subject's self-reporting questionnaires, medical records and endoscopic findings. We considered "long-term" follow-up to be >6 months with at least one more follow-up endoscopy.
RESULTS: One hundred and seventy (0.4%) subjects were endoscopically diagnosed as esophageal candidiasis and 141 subjects were AEC. Multivariate analysisrevealed that old age (¡Ã60 years) was an independent risk factor for AEC (OR, 1.862, p = 0.005). The number of subjects with long-term follow-up was 79 (195.3 person-years). Among these, AEC of 64 subjects (81.0%) had disappeared on the follow-up endoscopy and was not recurrent. The other 15 subjects had AEC diagnosed more than once on the follow-up endoscopy, and 5 of them were spontaneously healed during the follow-up period. The remaining 10 subjects whose candidiasis was sustained up to the last endoscopy did not complain of symptoms during the follow-up period, and their endoscopic findings did not worsen.
CONCLUSIONS: AEC is rare and old age is the only risk factor. AEC (asymptomatic esophageal candidiasis) does not require medical care because it is a self-limited disease.
Àú´Â ³»½Ã°æ °Ë»ç µµÁß ¹«Áõ»ó ½Äµµ ĵð´ÙÁõÀº ½½Â½ ¹«½ÃÇϱ⵵ ÇÕ´Ï´Ù. ÇǺΰú Àǻ簡 ¸ðµç Á¡¿¡ ´ëÇÏ¿© comment ÇÏÁö ¾Ê´Â °Íó·³...
³»½Ã°æ °á°úÁö °á·Ð¿¡´Â ¾ð±ÞÇÏÁö ¾Ê°í ÀÇ°ß¿¡ »ì¦ ±â·ÏÀ» ³²°ÜµÐ sense. ÈǸ¢ÇÕ´Ï´Ù.
4-5) 2009³â ¹Ì±¹ °¡À̵å¶óÀο¡ ¾ð±ÞµÈ ¹«Áõ»ó ĵð´ÙÁõ
2009³â Infectious Diseases Society of AmericaÀÇ °¡À̵å¶óÀÎ(Clinical Infectious Diseases 2009;48:503-35)¿¡ µû¸£¸é ¹«Áõ»ó candiduria´Â Ä¡·á°¡ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù.
±×·±µ¥ ÀÌ °¡À̵å¶óÀο¡´Â ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ¿¡ ´ëÇÑ ¾ð±ÞÀº ¾ø½À´Ï´Ù. ¹Ì±¹¿¡¼´Â '¹«Áõ»ó ½Äµµ ĵð´ÙÁõ'ÀÌ Áø´ÜµÇ´Â °æ¿ì°¡ °ÅÀÇ ¾ø±â ¶§¹®ÀÔ´Ï´Ù. ¿ÀÈ÷·Á ÀÌ·± ¹®ÀåÀÌ ÀÖ½À´Ï´Ù. "A diagnostic trial of antifungal therapy is appropriate before performing an endoscopic examination." ³»½Ã°æÀÌ ³Ê¹« ºñ½Î°í Á¢±Ù¼ºÀÌ ¶³¾îÁö¹Ç·Î ÀÇ½ÉµÇ¸é ¸ÕÀú Ç×Áø±ÕÁ¦ Ä¡·á¸¦ Çصµ ÁÁ´Ù´Â °ÍÀÔ´Ï´Ù. ´Þ¶óµµ ³Ê¹« ´Ù¸£±º¿ä.
¿©ÇÏÆ° Áõ»óÀÌ ¾øÀ¸¸é ¼Òº¯ ĵð´Ù´Â Ä¡·áÇÏÁö ¾Ê´Âµ¥ ½Äµµ ĵð´Ùµµ ¸¶Âù°¡Áö ¾Æ´Ò±î »ý°¢ÇØ º¾´Ï´Ù.
4-6) 2018³â 11¿ù »óºÎÀ§Àå°üÇ︮ÄÚ¹ÚÅÍÇÐȸ ±³À°ÀÚ·á
4-7) ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ YouTube °ÀÇ (2019)
5. Candida-infected gastric ulcer and cancer (ĵð´Ù °¨¿° À§±Ë¾ç°ú À§¾Ï)
À§±Ë¾ç ȤÀº ½ÊÀÌÁöÀå ±Ë¾ç¿¡ fungal colonizationÀÌ µ¿¹ÝµÇ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. ĵð´Ù °¨¿°Àº ±Ë¾ç Ä¡À¯ ¼Óµµ¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê½À´Ï´Ù. Ä¡·áµµ ´Þ¶óÁöÁö ¾Ê½À´Ï´Ù. Antifungal agent¸¦ Åõ¿©ÇÒ ÇÊ¿äµµ ¾ø½À´Ï´Ù. ±×³É PPI¸¸ ÁÖ¸é ±×¸¸ÀÔ´Ï´Ù.
ĵð´Ù °ü·Ã ±Ë¾çÀÇ ÀüÇüÀûÀÎ ¿¹ÀÔ´Ï´Ù. ĵð´Ù°¡ ¸ÕÀúÀÎÁö ±Ë¾çÀÌ ¸ÕÀúÀÎÁö ¾Ë ¼ö ¾øÁö¸¸ Àú´Â ±Ë¾çÀÌ ¸ÕÀú¶ó°í »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù.
Åë»óÀÇ À§±Ë¾ç Ä¡·á ÈÄ °æ°ú°üÂûÀε¥ ¿ÏÀüÈ÷ È£ÀüµÇ¾ú½À´Ï´Ù.
Candida °¨¿°ÀÌ µ¿¹ÝµÈ ±Ë¾çÀ» ¼³¸íÇÑ ¾î¶² Àú³Î (Hirasaki S. J Gastroenterol 1999;34:688-693)ÀÇ ÀϺθ¦ ¿Å±é´Ï´Ù. "Candida-infected gastric ulcer should be suspected in patients with a gastric submucosal tumor-like lesion with a thick, yellowish-white coated ulcer of unclear border on its summit, and this lesion should be distinguished from malignant diseases." ¿ì¸® Áõ·Ê¸¦ ±×´ë·Î ¼³¸íÇØ ÁÖ´Â °Í °°½À´Ï´Ù.
[À§±Ë¾ç + Candida]
'À§±Ë¾ç + Candida'¿´°í ±Ë¾ç¾à¸¸ ½áµµ È£ÀüµÇ¾ú½À´Ï´Ù. Follicular lymphomaµµ °¡Áö°í ÀÖ´ø ȯÀÚÀÔ´Ï´Ù.
[À§¾Ï + Candida]
Á¶Á÷°Ë»ç poorly differentiated carcinoma, Candida (+). À§¾Ï°ú ĵð´Ù°¡ ¸ðµÎ ³ª¿Â °æ¿ì¿´½À´Ï´Ù. Å« ±Ë¾çÇü À§¾Ï¿¡ ĵð´Ù°¡ ÀÚ¸®ÀâÀº °æ¿ì¶ó°í ÇÒ ¼ö ÀÖ½À´Ï´Ù. (EndoTODAY 20110106)
[2013-11-10 EndoTODAY¿¡ ´ëÇÑ ¾Öµ¶ÀÚ (C´ë K±³¼ö) ÆíÁö]
±³¼ö´ÔÀÇ EndoTODAY¿¡¼ ¸Å¹ø »õ·Î¿î Áö½Ä°ú ÇÔ²² ±ÕÇü ÀÖ´Â ½Ã¾ß¸¦ ¹è¿ì°í ÀÖ½À´Ï´Ù. ¿À´Ã ¸»¾¸ÇϽŠ³»¿ë°ú ºñ½ÁÇÑ ³»¿ëµéÀ» ±³¼ö´ÔÀÇ ±Û¿¡¼ ¸¹ÀÌ º¸°Ô µÇ´Âµ¥¿ä. ÀÌ·± ºÎºÐÀº ÇâÈÄ Clinical trialÀÌ ÀÖ¾î¾ß µÉ °ÍÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. ¹°·Ð ÀÌ·± ¾ÆÀÌÅÛÀÌ ¿¬±¸ÀÚ Ãø¸é¿¡¼ º¼ ¶§ º°·Î Àα⠾ø´Â ¾ÆÀÌÅÛÀÏ ¼öµµ ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÓ»óÁø·áÀÇ °¡À̵带 Á¦½ÃÇÏ¿© ÁÖ´Â °ÍÀº ¹«Ã´ Áß¿äÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù.
°Å½Ã°æÁ¦ÀûÀÎ °üÁ¡¿¡¼ º¼ ¶§ ¾îÂ¥ÇÇ ÀÚ¿øÀº ÇÑÁ¤µÇ¾î ÀÖ´Ù°í ¿©°Ü Áý´Ï´Ù. ¼³»ç Àý´ëÀû ÀÚ¿øÀÌ Áõ°¡ÇÑ´Ù Çصµ Àηù¿ª»ç¿¡¼ ÀÚ¿øÀÌ »ó´ëÀûÀ¸·Î dzÁ·ÇÑ ÀûÀº ¾ø¾ú´ø °Í °°½À´Ï´Ù. ÈçÈ÷ ÆÄÀ̸¦ Å°¿ö¾ß ÇÑ´Ù°í À̾߱â ÇÏÁö¸¸.... ÀÌ°Í ¿ª½Ã ´Ù¸¥ ¿µ¿ªÀÇ ÀÚ¿øÀ» ÀÌÂÊ¿¡¼ »ç¿ëÇÏ°Ú´Ù´Â Àǹ̰¡ ÀüÇô ³»Æ÷µÇÁö ¾Ê¾Ò´Ù°í ÇÒ ¼ö ´Â ¾ø´Â °ÍÀ̶ó°í »ý°¢ÇÕ´Ï´Ù.
°á±¹ ÀÌ·± ³íÀïÀÇ ¿äÁö´Â ºÒÇÊ¿äÇÑ medical practice¿¡ »ç¿ëµÇ´Â ÀÚ¿øÀÌ ÀÖ´Ù¸é À̸¦ ÇâÈÄ ÁÙÀÌ°í ÀÌ ÀÚ¿øÀ» ²À ÇÊ¿äÇÑ È¤Àº µµ¿òÀÌ µÇ´Â medical practice·Î ÀçÆíÇÏ´Â °ÍÀ̸ç ÀÌ°ÍÀº ÀÇÇÐÀû ³í¸®¿¡¼ º¸³ª »çȸ°æÁ¦Àû ÀÚ¿ø ¹èºÐÀÇ ³í¸®¿¡¼ º¸³ª Ÿ´çÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù. ƯÈ÷ Çѱ¹°ú °°ÀÌ ³»½Ã°æÀ» Àü±¹¹ÎÀÌ ÀÚÁÖ ¹Þ´Â ³ª¶ó¿¡¼´Â Asymptomatic endoscopic findingÀÌ Clinically substantial consequence¿Í ¿¬°üÀÌ ÀÖ´ÂÁö¿¡ ´ëÇÑ ¿¬±¸°¡ ÇÊ¿äÇϸ®¶ó°í »ý°¢ÇÕ´Ï´Ù. Symptom base·Î ȯÀÚ¸¦ Á¢±ÙÇÏ´Â ±¹°¡¿¡¼´Â ÀÌ·± ¿¬±¸¸¦ ÇÒ ¼öµµ ¾ø°í ÇÒ ÇÊ¿äµµ ¾øÀ» °Í °°½À´Ï´Ù.
¹®Á¦´Â ÀÌ·ÐÀûÀ¸·Î´Â Ÿ´çÇÏ°ÚÁö¸¸, Àΰ£ÀÌ Àΰ£°ú »óÈ£ÀÛ¿ëÇÏ´Â »çȸ¶ó´Â °ø°£ÀÌ Á÷¼±ÀûÀÎ ³í¸®¸¸À¸·Î ¿òÁ÷ÀÌ´Â °ÍÀÌ ¾Æ´Ï¸ç ³í¸®º¸´Ù´Â ¿å¸Á°ú ÀÌ¿¡ ±â¹ÝÇÑ Á¤¼°¡ ´õ Å« ÀÛ¿ëÀ» ÇÏ´Â ¶§°¡ ¸¹ÀºÁö¶ó ¼²ºÒ¸® ¹¹¶ó°í ¾ð±ÞÇϱ⵵ ¾î·Á¿î °Í °°½À´Ï´Ù.
ÀÇÇп¡¼ ÈçÈ÷ ÀÌ¿ëµÇ´Â Evidence¶õ Åë°èÀû ±Í³³¹ý¿¡ ±â¹ÝÇÑ evidence¸¦ À̾߱â Çϴµ¥ ÀÌ·± Evidence°¡ ¾øÀ» ¶§´Â ±âÁ¸ Áö½Ä¿¡ ±â¹ÝÇÑ ¿¬¿ªÀû »ç°í·Î ¹®Á¦¸¦ Ç® ¼ö ¹Û¿¡ ¾øÀ» °Í °°´Ù´Â »ý°¢À» ÇÕ´Ï´Ù. ¹°·Ð ƯÁ¤ »ç¾È¿¡ ´ëÇÑ Evidence¸¦ ¸¸µé±â À§ÇÑ ³ë·ÂÀ» °ÔÀ»¸® ÇÏÁö ¸»¾Æ¾ß ÇÏ°ÚÁö¸¸¿ä.
[2014-11-12. ¾Öµ¶ÀÚ Áú¹®]
Ç×»ó °¨»çÇÑ ¸¶À½À¸·Î ¸ÞÀÏÀ» Àаí ÀÖ½À´Ï´Ù. ±âÃÊÁö½ÄÀÎ °Í °°¾Æ¼ ¸î ¹ø ¸Á¼³¿´Áö¸¸, ±×·¡µµ °è¼Ó ¹°À½ÀÌ ³²¾Æ ÀÖ¾î¼ ¿©Âã°íÀÚ ÇÕ´Ï´Ù. °Ç°°ËÁøÀ¸·Î ³»½Ã°æ °Ë»ç¸¦ ¹ÞÀº ¼ö°ËÀÚ Áß °¡²û ½Äµµ ĵð´ÙÁõÀÌ È®Àε˴ϴÙ. ´ëºÎºÐ ¸é¿ªÀúÇÏÁúȯÀ̳ª ½ºÅ×·ÎÀÌµå °°Àº ¸é¿ª¾ïÁ¦Á¦¸¦ »ç¿ëÇÏ´Â °æ¿ì´Â ¾Æ´Ï¾ú½À´Ï´Ù. °ü·Ã ±âÀúÁúȯÀÌ ¾ø°í À½½ÄÀ» »ïų ¶§ ºÒÆí°¨À̳ª ÅëÁõÀÌ ¾ø´Ù¸é ¾à¹°Ä¡·á¸¦ ¹ÞÀ» ÇÊ¿ä°¡ ¾ø´Ù°í ¼³¸íµå¸³´Ï´Ù.
¹®Á¦´Â ½Äµµ ĵð´ÙÁõ¿¡ ´ëÇØ ¼ö°ËÀÚ¿¡°Ô ¼³¸íÀ» ÇÏ´Ù º¸¸é ¸é¿ª±â´ÉÀÌ ÀúÇÏµÈ °æ¿ì¿¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù°í ¾ð±ÞÇÏ°Ô µË´Ï´Ù. ¼ö°ËÀÚµµ Àúµµ °°Àº ´À³¦À̶ó°í »ý°¢µÇ´Âµ¥... Ȥ½Ã ¸é¿ª±â´ÉÀÌ ¶³¾îÁö°Ô ÇÏ´Â ±âÀúÁúȯÀÌ ¼û¾îÀÖ´Â °Ç ¾Æ´ÑÁö ÂòÂòÇÑ »ý°¢ÀÌ ½ºÃÄ°©´Ï´Ù...^^ EndoTODAY¿¡¼ ½Äµµ ĵð´ÙÁõ¿¡ ´ëÇؼµµ Çѹø ´Ù·ïÁֽøé ÁÁ°Ú½À´Ï´Ù.
Àú´Â (Ä¡·á´ë»ó ¼±Á¤ ¿Ü¿¡µµ) ¹®Áø»ó °ü·Ã ±âÀúÁúȯÀÌ È®ÀεÇÁö ¾ÊÀ¸¸é Ãß°¡Àû °Ë»ç(screening test)°¡ ÇÊ¿äÇÑÁö ±Ã±ÝÇÕ´Ï´Ù. °Ë»ç Á¾·ùµµ ÃßõÇØÁֽøé ÁÁ°Ú±¸¿ä.
[2014-11-13. ÀÌÁØÇà ´äº¯]
¹«Áõ»ó ĵð´ÙÁõ¿¡ ´ëÇؼ´Â Àúµµ ¾ÆÁ÷ ÀÔÀå Á¤¸®°¡ ³¡³ªÁö ¾Ê¾Ò½À´Ï´Ù. Á¶Á÷°Ë»çµµ ¹Ï±â ¾î·Æ°í, Ä¡·áÇصµ ¶Ç »ý±â´Â »ç¶÷µµ ¸¹°í, Ä¡·áÇÏÁö ¾Ê¾Æµµ ¾ø¾îÁö´Â »ç¶÷µµ ¸¹½À´Ï´Ù. ¿¬±¸´Â °ÅÀÇ ¾ø½À´Ï´Ù. ±×³É °³ÀÎÀû »ý°¢ ¸î°³¸¦ ½á º¼ »ÓÀÔ´Ï´Ù.
1) Grade IV ½Äµµ ĵð´ÙÁõ: anti-HIV µî ¸é¿ªÁúȯ¿¡ ´ëÇÑ °Ë»ç°¡ ÇÊ¿äÇÕ´Ï´Ù. Ä¡·á´Â ÇÕ´Ï´Ù.
2) Grade III ½Äµµ ĵð´ÙÁõ: anti-HIV µî ¸é¿ªÁúȯ¿¡ ´ëÇÑ °Ë»ç°¡ ÇÊ¿äÇÑÁö Àß ¸ð¸£°Ú½À´Ï´Ù. ÇØ º¸´Â °Íµµ ÁÁÀ» °Í °°½À´Ï´Ù. Ä¡·á´Â ÇÕ´Ï´Ù.
3) Grade II ½Äµµ ĵð´ÙÁõ: Á¶Á÷°Ë»ç Á¤µµ´Â ÇØ º¾´Ï´Ù. ±×·¯³ª ĵð´ÙÁõÀÌ Áø´ÜµÇ¾îµµ, Áø´ÜÀÌ µÇÁö ¾Ê¾Æµµ Ä¡·á´Â ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù. ±¸° û°á¿¡ À¯ÀÇÇÏ°í, Àú³á ´Ê°Ô ½Ä»çÇÏÁö ¸»¶ó°í ±ÇÇÕ´Ï´Ù. (2020-4-28. ¿äÁòÀº Á¶Á÷°Ë»çµµ ÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. Á¶Á÷°Ë»ç¸¦ Çؼ ÀǹÌÀÖ´Â °á°ú°¡ ³ª¿Â ÀûÀÌ ÇÑ ¹øµµ ¾ø¾ú½À´Ï´Ù. Á¶Á÷°Ë»ç¿¡¼ ³ª¿Ô´Âµ¥ Åõ¾àÀ» ÇÏÁö ¾ÊÀ¸¸é ÀÌ»óÇÏ°Ô »ý°¢Çϴ ȯÀÚ°¡ ÀÖÀ» »ÓÀÔ´Ï´Ù. Á¶Á÷°Ë»ç¿¡¼ ³ª¿Ô´Âµ¥ Åõ¾àÇÏÁö ¾ÊÀ¸¸é ´õ¿í ÀÌ»óÇÏ°Ô »ý°¢Çϴ ȯÀÚµµ ¸¹¾Ò½À´Ï´Ù. ±×·¡¼ ÀÌÁ¦´Â Á¶Á÷°Ë»çÁ¶Â÷µµ ÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù.)
4) Grade I ½Äµµ ĵð´ÙÁõ: »çÁø ÇÑ Àå Âï¾îµÎ°í °á°úÁö¿¡ ¾²Áö ¾Ê½À´Ï´Ù. Á¶Á÷°Ë»çµµ ÇÏÁö ¾Ê½À´Ï´Ù. ±×³É ¹«½ÃÇÕ´Ï´Ù.
±×·±µ¥ 1)¿¡¼ 4)±îÁö Á¦½ÃÇÑ ¹æ¹ýÀº Á¦ ȯÀÚ¸¦ Á¦°¡ °Ë»çÇÏ°í Á¦°¡ ¼³¸íÇÑ °æ¿ì¿¡¸¸ Àû¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ´Ù¸¥ »ç¶÷ÀÌ °Ë»çÇÏ°í, ´Ù¸¥ »ç¶÷ÀÌ ¼³¸íÇÒ ¶§¿¡´Â ÀüÇô ´Ù¸¥ ¹æ¹ýÀ» ¾µ ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. Áø´Ü°ú Ä¡·á ¿øÄ¢ÀÌ Á¤ÇØÁ® ÀÖÁö ¾Ê±â ¶§¹®ÀÔ´Ï´Ù. ±×·¡¼ 5)¹øÀ» »ý°¢ÇØ¾ß ÇÕ´Ï´Ù.
5) ³»½Ã°æ Á¶Á÷°Ë»ç·Î ĵð´ÙÁõÀÌ È®ÀÎµÈ ÈÄ ÀÇ·ÚµÈ °æ¿ì:
°Ç°°ËÁø ¼¾ÅÍ¿¡¼ ÀÇ·ÚµÈ È¯ÀÚÀÎ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ¹Ì °ÇÁø¿¡¼ "¼Òȱ⳻°ú·Î °¡¼ »ó¼¼È÷ ¼³¸íÀ» µè°í ÀûÀýÈ÷ Ä¡·á¹ÞÀ¸¼¼¿ä."¶ó´Â Ä£ÀýÇÑ ¼³¸íÀ» µéÀº »óÅÂÀÌ°í, '½Äµµ ĵð´ÙÁõ'À̶ó°í Å©°Ô ÀûÈù °á°úÁö¸¦ °¡Áö°í ÀÖ´Â ¼öÁøÀÚ¿¡°Ô "º° Àǹ̰¡ ¾ø½À´Ï´Ù. ±¸° û°á¿¡ À¯ÀÇÇÏ°í, Àú³á ´Ê°Ô ½Ä»çÇÏÁö ¸¶¼¼¿ä. ÀÌ Á¤µµÀÇ ½Äµµ °õÆÎÀÌ´Â ¹«½ÃÇصµ ÁÁ½À´Ï´Ù. ¾àÀº ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù."¶ó°í ¸»Çϱâ´Â ¾î·Æ½À´Ï´Ù. ±×³É fluconazole 50 mg bid¸¦ 7ÀÏ Ã³¹æÇÏ´Â ¼ö ¹Û¿¡... ³»°ú ¿Ü·¡·Î °¡¼ »ó¼¼È÷ ¼³¸íµè°í Ä¡·á¹ÞÀ¸¶ó°í ¾È³»¹ÞÀº »ç¶÷¿¡°Ô ¾àÀ» ¾È ÁÖ±â´Â ¾î·Æ½À´Ï´Ù.
¿äÄÁµ¥ ÀÌ·¸½À´Ï´Ù. ¾ÆÁÖ ½ÉÇÑ °æ¿ì°¡ ¾Æ´Ï¶ó¸é ÀÇ·ÚµÈ È¯ÀÚ¿¡°Ô´Â ¾àÀ» ÁÖ°í Á¦°¡ Áø´ÜÇÑ È¯ÀÚ¿¡°Ô´Â ¾àÀ» ÁÖÁö ¾Ê½À´Ï´Ù. ¸»µµ ¾È µÇ´Â ¾ïÁö ÁÖÀåÀ̶󱸿ä? Çö½ÇÀûÀ¸·Î ¾î¿ ¼ö ¾ø½À´Ï´Ù. ¾àÀ» ÁÖ¾î¾ß ÇÏ´ÂÁö ÁÖÁö ¾Ê¾Æµµ ÁÁÀºÁö ¸íÈ®ÇÏÁö ¾ÊÀº »óȲ¿¡¼ ¾àÀ» ±â´ëÇÏ°í ¸Ö¸®¼ ¿Â ȯÀÚ¿¡°Ô ¾àÀ» ÁÖÁö ¾Ê±â´Â ¾î·Æ½À´Ï´Ù. º¸Åë ¾öû ȸ¦ ³À´Ï´Ù. ÀÜ¶à °ÆÁ¤ÇÏ°í ¸Ö¸® ã¾Æ¿Í ÇÑÂüÀ» ±â´Ù·Á Áø·á¸¦ Çߴµ¥ "º°°Å ¾Æ´Õ´Ï´Ù"¶ó°í µéÀ¸¸é ¾öû ȸ¦ ³À´Ï´Ù. ´ç¿¬ÇÑ ÀÏÀÔ´Ï´Ù. ³»½Ã°æÀ» ÇÑ Àǻ簡 Áø´ÜÀ» ºÙÀÌÁö ¾Ê´øÁö, °ËÁø¼¾ÅÍ¿¡¼ Á÷Á¢ ¼³¸íÇÏ°í Åõ¾à¾øÀÌ Áö³»¶ó°í ±ÇÇÏÁö ¾ÊÀ¸¸é ´Ù¸¥ µµ¸®°¡ ¾ø½À´Ï´Ù. ÀÇ·Ú¹ÞÀº ³»°ú ÀÇ»ç´Â ¾àÀ» ÁÙ ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. Follow-upÀ» ÇÒ ¼ö ¾ø´Â »óȲ¿¡¼´Â ´õ¿í ±×·¸½À´Ï´Ù.
Åõ¾à ¿©ºÎ´Â Áúº´ ÀÚü·Î¸¸ °áÁ¤µÇ´Â °ÍÀÌ ¾Æ´Õ´Ï´Ù. Á¦¹Ý ¿©°ÇÀÌ Åõ¾à ¹æÇâÀ» °¡¸£Å°°í ÀÖÀ¸¸é Åõ¾àÇÒ ¼ö ¹Û¿¡ ¾ø°Ô µË´Ï´Ù. Á¦¹Ý ¿©°ÇÀÌ Åõ¾à¾ø´Â °æ°ú°üÂû ÂÊÀ» °¡¸£Å°¸é °æ°ú°üÂûÀ» ¼±ÅÃÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù. ÀÌ·± ÀÔÀå¿¡¼ "ÀÇ·Ú=Åõ¾à"ÀÔ´Ï´Ù.
°á±¹ ¹«Áõ»ó ¼ºÀÎÀÇ ³»½Ã°æ¿¡¼ ¹ß°ßµÇ´Â »ç¼ÒÇÑ ¼Ò°ßÀ» ¾î¶»°Ô Æò°¡ÇÏ°í ¾î¶»°Ô °ü¸®ÇÒ °ÍÀÎÁö, ³íÀǵµ ÇÏÁö ¾Ê°í ÇÕÀǵµ µÇÁö ¾ÊÀº »óÅ¿¡¼ °Ë»ç°¡ ½ÃÇàµÈ °á°ú·Î¼ÀÇ È¥¼±ÀÔ´Ï´Ù. Áö±ÝºÎÅÍ¶óµµ µ¥ÀÌŸ¸¦ ¸ðÀ¸°í, È°¹ßÈ÷ Åä·ÐÇÏ¿© ÇÕÀÇµÈ ÀÇ°ßÀ» ¸¸µé¾î¾ß ÇÕ´Ï´Ù. Àá½Ã ÈïºÐÀ» °¡¶ó¾ÉÈ÷°í ¼Óµµ¸¦ ÁÙ¿©¾ß Ç®¸®´Â ¹®Á¦ÀÔ´Ï´Ù.
[2013-7-11. S º´¿ø chief resident Áú¹®]
ÃÖ±Ù ½Äµµ¿¡¼ ÀÚÀßÇÑ whitish plaque °°Àº º´º¯À» º¸¾Ò½À´Ï´Ù. ¹°·Î Àß ¾Ä°ÜÁöÁö ¾Ê°í, acanthosis º¸´Ù´Â ¸í¹éÈ÷ whitish ÇÏ¿© Candida°¡ ÀǽɵǴ º´º¯À̾ú½À´Ï´Ù.Áõ·Ê 1: M/49, underlying disease (-), Sx : non-specific
Áõ·Ê 2: F/61, ´ç´¢º´, previous candida Hx (+)
2¹ø ȯÀÚºÐÀº Á¶Á÷°Ë»ç·Î Candida·Î Áø´ÜÀÌ µÇ¾ú½À´Ï´Ù. Áú¹®Àº Á¶Á÷°Ë»ç°¡ negative ÀÎ 1¹ø ȯÀÚ¿¡¼ Candida¶ó°í ºÒ·¯µµ ÁÁÀ»Áö¿ä? ³»½Ã°æ »çÁø¸¸ ºÁ¼´Â ºñ½ÁÇØ º¸ÀÔ´Ï´Ù. Áõ»óÀÌ Æ¯ÀÌÀûÀÌÁö ¾Ê°í underlying disease°¡ ¾ø°í Àǽɸ¸µÇÁö Á¶Á÷°Ë»ç·Î È®ÀεÇÁö ¾Ê´Â »ç¶÷µé¿¡¼ Candida¿¡ ÁØÇØ Ä¡·á°¡ ÇÊ¿äÇÒÁö ¹®Àǵ帳´Ï´Ù.
[2013-7-17. ÀÌÁØÇà ´äº¯]
1. ½Äµµ CandidaÁõÀÇ Á¶Á÷°Ë»çÀÇ sensitivity´Â ±×¸® ³ôÁö ¾Ê½À´Ï´Ù. ƯÈ÷ ¹«Áõ»ó ¼ºÀÎÀÌ°í Áõ»óÀÌ ½ÉÇÏÁö ¾ÊÀº ȯÀÚ¿¡¼´Â ´õ¿í ³·½À´Ï´Ù. µû¶ó¼ Á¶Á÷°Ë»ç¿¡¼ ³ª¿À¸é Candida ½Äµµ¿°À¸·Î È®ÁøÇÒ ¼ö ÀÖÁö¸¸ ³ª¿ÀÁö ¾Ê¾Ò´Ù°í ¾Æ´Ï¶ó°í ¸»ÇÒ ¼ö ¾ø½À´Ï´Ù.
2. µÎ¹ø° Áõ·Êó·³ ¹«Áõ»óÀÌ°í °æÇÑ Candida ½Äµµ¿°À» ²À Ä¡·áÇØ¾ß ÇÏ´ÂÁö ¸íÈ®ÇÏÁö ¾Ê½À´Ï´Ù. Ä¡·áÇÏÁö ¾Ê¾Æµµ ÁÁ´Ù´Â ÁÖÀåµµ ¸¹½À´Ï´Ù. Àúµµ Ä¡·áÇÏÁö ¾Ê¾Æµµ µÈ´Ù°í »ý°¢ÇÕ´Ï´Ù. ±×·¯³ª Çö½ÇÀûÀ¸·Î Á¶Á÷°Ë»ç·Î È®ÀαîÁö µÇ¾ú´Âµ¥ Ä¡·áÇÏÁö ¾Ê¾Æµµ µÈ´Ù´Â °ÍÀ» ȯÀÚ¿¡°Ô ¼³µæÇϱⰡ ½±Áö ¾Ê½À´Ï´Ù. ±×·¡¼ ±×³É fluconazole 1ÁÖÀÏ Åõ¾àÇÏ°ï ÇÕ´Ï´Ù. Á¦ ½º½º·Î »ý°¢°ú ÇൿÀÌ ´Ù¸£±â ¶§¹®¿¡ ´Ã °í¹ÎÇÕ´Ï´Ù. ÁÁÀº ¿¬±¸ ÁÖÁ¦°¡ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. ´©±º°¡ ÁÁÀº ¿¬±¸·Î Á¦ °í¹ÎÀ» ÇØ°áÇØ Áֽñ⠹ٶø´Ï´Ù.
3. ù Áõ·Êó·³ ¹«Áõ»óÀÌ°í °æÇÑ Candida ½Äµµ¿°ÀÌ ÀǽɵǴµ¥ Á¶Á÷°Ë»ç·Î ³ª¿ÀÁö ¾Ê´Â °æ¿ì´Â Ä¡·áÇÏÁö ¾Ê½À´Ï´Ù. Á¶Á÷°Ë»ç·Î È®ÀÎµÈ °æ¿ì¶óµµ Ä¡·áÇÒÁö ¸»Áö¸¦ °í¹ÎÇÏ´Â »óȲ¿¡¼, Á¶Á÷°Ë»ç¿¡¼ ³ª¿ÀÁö ¾ÊÀº °Í±îÁö °í¹ÎÇÏ´Â °ÍÀº ÀÏÁ¾ÀÇ È£»ç¶ó°í »ý°¢ÇÕ´Ï´Ù. °£È¤ fluconazoleÀ» µå¸®°í ÃßÀû°üÂû¿¡¼ Candida°¡ ¾ø¾îÁö´Â ¾ç»óÀ» º¸°í Áø´ÜÇÏ´Â ºÐµµ °è½ÃÁö¸¸, Àú´Â ±×·¸°Ô±îÁö ÇÒ ÇÊ¿ä´Â ¾ø´Ù°í »ý°¢ÇÕ´Ï´Ù.
4. ¸é¿ªÀÌ Á¤»óÀÎ »ç¶÷ÀÇ asymptomatic esophageal candidiasis¿¡ ´ëÇÑ ³í¹®Àº ã¾Æº¸Áú ¸øÇß½À´Ï´Ù. ±×·¯³ª AIDS ȯÀÚ¿¡¼´Â Á¾Á¾ ³í¹®ÀÌ ÀÖ½À´Ï´Ù. Asymptomatic esophageal candidiasis¶óµµ ½ÉÇÏ´Ù°í »ý°¢µÇ¸é ¹Ýµå½Ã HIV antibody °Ë»ç¸¦ ÇØ¾ß ÇÑ´Ù´Â Á¡Àº ÀØÁö ¸¶½Ã±â ¹Ù¶ø´Ï´Ù.
[2014-11-14. ¾Öµ¶ÀÚ Áú¹®°ú ÀÌÁØÇàÀÇ ´äº¯]
1.¾ËÄݸ¯½º³ª ´ç´¢¿Í °°Àº ¸é¿ªÀúÇÏ ¿äÀÎÀÌ ÀÖÀ¸³ª ¹«Áõ»óÀÌ°í Grade I, IIÀÎ °æ¿ì (¹«Áõ»ó, À§Çè¿äÀÎÀÌ ¾ø´Â º¸ÅëÀÇ ¼ºÀÎó·³) Ä¡·áÇÏÁö ¾Ê¾Æµµ µÉ±î¿ä? Grade III, IV´Â Ä¡·áÇÏ´Â °ÍÀº ¾Ë°Ú´Âµ¥... Grade I, II ¿¡¼ ¹«Áõ»ó, ¸é¿ªÀúÇÏ À§Çè¿äÀÎÀÌ ÀÖ´Â °æ¿ì´Â ¾î¶»°Ô ÇϽôÂÁö Áú¹® µå¸³´Ï´Ù.
[´äº¯] °³ÀÎÀûÀ¸·Î´Â Ä¡·áÇÏÁö ¾Ê¾Æµµ ÁÁ´Ù°í »ý°¢ÇÕ´Ï´Ù. Alcoholics³ª ´ç´¢º´ ȯÀÚ¿¡¼´Â Ä¡·áÇصµ ³ª»ÚÁö´Â ¾ÊÀ» °Í °°½À´Ï´Ù. Àú´Â »ç¼ÒÇÑ Candida ÀÇ½É ¼Ò°ßÀº Á¤È®ÇÑ Áø´ÜÀ» À§ÇÏ¿© ³ë·ÂÇÏÁö ¾Ê°í ±×³É »çÁø ÇÑÀå Âï¾îµÎ´Â °ÍÀ¸·Î ¸¶¹«¸®ÇÏ°í ÀÖ½À´Ï´Ù. Á¶Á÷°Ë»ç¸¦ Çϰųª °á·Ð¿¡ ĵð´ÙÁõÀ̶ó°í ½á¹ö¸®¸é, ³ªÁß¿¡ ÀÌ·¯Áöµµ Àú·¯Áöµµ ¸øÇÏ´Â »óȲ¿¡ ºüÁö±â ½±½À´Ï´Ù. ³»½Ã°æÀ» ÇÏ¸é¼ ÀÓ»óÀû ÀÇÀǸ¦ °í·ÁÇÏ¿© ÇÊ¿äÇÑ °Í¸¸ °á°úÁö¿¡ ¾´´Ù´Â »ý°¢ÀÔ´Ï´Ù.
2. »çÁø ÷ºÎ ÇÏ¿´´Âµ¥ 54¼¼ ´ç´¢, ¾ËÄݸ¯½º·Î Áõ»óÀº ¾ø´Âµ¥ ½ÄµµÁ¡¸·ÀÌ Àü¹ÝÀûÀ¸·Î Á¶ÀâÇÏ°í, whitsh plaques ÀÌ ÀÖ¾ú°í »óÀýÄ¡·ÎºÎÅÍ 30cm ºÎÀ§ erosionÀÌ ÀÖ¾î Bx. Çß½À´Ï´Ù. °á°ú¿¡¼ a few eosinophil À̶ó´Â °á°ú°¡ ³ª¿Ô´Âµ¥ ÀÌ °á°ú´Â ±×³É ¹«½ÃÇصµ µÇ´Â °ÇÁö¿ä?
[´äº¯] »çÁø¸¸À¸·Î ¸íȮġ ¾ÊÀ¸³ª º° Àǹ̴ ¾øÀ» °Í °°½À´Ï´Ù. È£»ê±¸°¡ ½Äµµº®¿¡ ¾öû ¸¹ÀÌ Ä§À±Çϴ ȣ»ê±¸½Äµµ¿°À̶ó´Â º´ÀÌ ÀÖ±â´Â ÇÕ´Ï´Ù¸¸, ÀÏ´Ü Áõ»óÀÌ ÀÖÀ» ¶§ Ä¡·áÇÏ´Â º´À̱⠶§¹®¿¡ Áõ»ó(dysphagia)ÀÌ ¾ø´Ù¸é ¹«½ÃÇصµ ÁÁ°Ú½À´Ï´Ù.
3. ¸¶Áö¸· È»ìÇ¥ »çÁøÀº Á¦°¡ óÀ½ ¹ß°ßÇÑ ½Äµµ¾Ï »çÁøÀÔ´Ï´Ù. Á¶±â½Äµµ¾ÏÀÌ°ÚÁÒ? ±×³É Áö³ªÄ¥»· Çߴµ¥ ´«¿¡ °Å½½·Á Á¶Á÷°Ë»ç Çߴµ¥ squamous cell carcinoma°¡ ³ª¿Ô½À´Ï´Ù. ºÎ²ô·´Áö¸¸ ±â»Û ¸¶À½¿¡ °øÀ¯ÇØ º¾´Ï´Ù.
[´äº¯] ½Äµµ¾Ï¿¡ µ¿ÀÇÇÕ´Ï´Ù. ´ëºÎºÐ ³õÄ¥ ¼ö ¹Û¿¡ ¾ø´Â ÀÛÀº ½Äµµ¾ÏÀ» Àß ¹ß°ßÇϼ̽À´Ï´Ù. ¼ö°í ¸¹À¸¼Ì°í ÃàÇÏÇÕ´Ï´Ù.
[2016-9-19. ¾Öµ¶ÀÚ Áú¹®]
°Ç° ¼ºÀο¡¼ Á¶Á÷ °Ë»ç »ó Candida esophagitis ³ª¿À¸é ¾î¶»°Ô Çϳª¿ä? ¾Ç°£ÀÇ dysphagia°¡ ÀÖ´Ù°í ÇÕ´Ï´Ù. ¸é¿ª¿¡ ¹®Á¦°¡ ÀÖ´ÂÁö °Ë»çÇÒ ÇÊ¿ä´Â ¾ø³ª¿ä? ¾àÀ» ¸Ô¾î¼ ÇØ°¡ ¾ø´Ù¸é Åõ¾àÀ» ¿øÇϽôµ¥ ¹«¾ùÀ» ÃßõÇÒ±î¿ä?
[2016-9-19. Àü¹®°¡ ´äº¯ (S º´¿ø ±³¼ö)]
°ÇÁøÀÚ·á ºÐ¼®°á°ú Á¤»ó¸é¿ªÀÇ ¹«Áõ»ó Candida esophagitis¿¡¼ Ç×Áø±ÕÄ¡·á´Â °æ°ú¿¡ ¾Æ¹«·± ¿µÇâÀÌ ¾ø´Ù°í ÆǴܵǹǷΠġ·áÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. ¾à°£ÀÇ dysphagia´Â Candida esophagitis¿Í °ü·ÃÀÌ ÀûÀ» °ÍÀ¸·Î »ý°¢µÇ¹Ç·Î ¿ª½Ã °æ°ú°üÂûÇÒ ¼ö ÀÖÀ» °Í °°½À´Ï´Ù.°Ë»ç¸¦ È®ÀÎÇÑ´Ù¸é °£¿°Ç×ü, HIV Ç×ü, TFT °Ë»ç°á°ú µîÀº ì°Üº¸°í ¾øÀ¸¸é ½ÃÇàÇÏ°í ÀÖ½À´Ï´Ù. ¾àÀº fluconazole 100mg qd 7-10ÀÏ Ã³¹æÀÔ´Ï´Ù.
[2016-9-19. ¾Öµ¶ÀÚ Áú¹®]
70´ë ³²ÀÚ È¯ÀÚ·Î 10³â Àü Âë Á¶±âÀ§¾ÏÀ¸·Î STG with B-I anastomosis ½ÃÇà¹ÞÀº °Í ÀÌ¿Ü¿¡ ƯÀ̺´·ÂÀº ¾ø´Â ºÐÀÔ´Ï´Ù. 2³â Àü odynophagia·Î ³»¿øÇÏ¿© ³»½Ã°æ ½ÃÇàÇÏ¿´°í ½Äµµ ÀüÀå¿¡ °ÉÃÄ esophageal candidiasis°¡ ÀÖ¾î oral fluconazole Åõ¿©ÇÏ¿´½À´Ï´Ù. 2³â°£ 13¹øÀÇ ¹Ýº¹ÀûÀÎ µ¿ÀÏÇÑ Áõ»óÀ¸·Î ³»¿øÇÏ¿© Ä¡·á ¹Þ¾Ò½À´Ï´Ù. ¿À´Ãµµ °°Àº Áõ»óÀ¸·Î ³»¿øÇÏ¿´°í, ¿ª½Ã ³»½Ã°æ¿¡¼ ½Äµµ Àü¹Ý¿¡ candidiasis°¡ ÀÖ¾ú½À´Ï´Ù.
Candidasis¿¡ ´ëÇØ Ã£¾Æº¸´Ù°¡ Clin Infect Dis 2009¿¡ ½Ç¸° °¡À̵å¶óÀÎÀ» º¸´Ï, recurrent esophageal candidiasis¿¡ ´ëÇؼ´Â fluoconazole 100-200m¸¦ ÁÖ 3ȸ Åõ¿©ÇÒ ¼ö ÀÖ´Ù°í µÇ¾î ÀÖ¾ú½À´Ï´Ù. ½ÇÁ¦·Î ÀÌ·¸°Ô Ä¡·áÇϽôÂÁö¿ä? Recurrent esophageal candidiasis¿¡ ´ëÇÑ Ä¡·á¿¡ ´ëÇØ ¹®Àǵ帳´Ï´Ù.^^
[2016-9-19. ¼Òȱ⳻°ú ¹Î¾ç¿ø ±³¼ö´Ô ´äº¯]
»ï¼º¼¿ïº´¿ø °ÇÁø ÀÚ·á ºÐ¼® °á°ú ½Äµµ ĵð´ÙÁõÀÌ ¹ß°ßµÈ »ç¶÷Àº Ä¡·á ¿©ºÎ¿Í »ó°ü¾øÀÌ 20% ÀÌ»ó ´ÙÀ½ ³»½Ã°æ¿¡¼µµ ĵð´Ù°¡ ¹ß°ßµÇ¾ú½À´Ï´Ù. ±×·¡¼ Àú´Â ĵð´Ù°¡ »ý±æ »ç¶÷Àº °á±¹ »ý±ä´Ù°í »ý°¢Çϸç ÀϺΠsubclinical T cell dysfunction °ú ¿¬°üÀÌ ÀÖÁö ¾Ê³ª ÃßÃøÇÕ´Ï´Ù. °Å±â¿¡ ±¸Á¶Àû factor (ÇùÂø, ½ÉÇÑ ¿ª·ù?)°¡ ´õÇØÁö¸é ´õ ¶Ñ·ÇÇØÁö´Â °Ô ¾Æ´Ñ°¡ ÇÕ´Ï´Ù.
¾ð±ÞµÈ ¹Ì±¹ °¡À̵å¶óÀÎ(Clinl Infect Dis 2009)Àº ´ëºÎºÐ AIDS ȯÀÚ ´ë»ó ¿¬±¸ °á°ú¸¦ ¹ÙÅÁÀ¸·Î ¸¸µé¾î Á®¼ Ä¡·á°¡ Á¶±Ý °ÇÑ °æÇâÀÌ ÀÖ½À´Ï´Ù. °³ÀÎÀûÀ¸·Î prophylactic treatment °æÇèÀº ¾ø½À´Ï´Ù. ´ë½Å Áõ»óÀÌ ½Äµµ ĵð´ÙÁõ¿¡ ÀÇÇØ ¹ß»ýÇÑ °ÍÀÎÁö ¸íÈ®È÷ ÇÏ°í, ´Ù¸¥ ±¸Á¶Àû ¿äÀÎÀº ¾ø´ÂÁö È®ÀÎÇØ¾ß ÇÒ °Í °°½À´Ï´Ù.
¸¶Áö¸·À¸·Î´Â oral fluconazoleÀÌ È¿°úÀûÀÎÁö È®ÀÎÀÌ ÇÊ¿äÇÕ´Ï´Ù. Ä¡·á Ƚ¼ö°¡ ³Ê¹« Àæ¾Æ recurrent¶ó°í ÆÇ´ÜÇϱ⺸´Ù´Â persistent ÇÑ °ÍÀ¸·Î ºÁ¾ß ÇÏÁö ¾ÊÀ»±î ÇÕ´Ï´Ù. ÀÌ °æ¿ì´Â fluconazole refractory case·Î Á¤ÀÇÇÏ°í itraconazoleÀ̳ª Amphotericin-B µî ´Ù¸¥ ¾àÁ¦°¡ ÇÊ¿äÇÒ ¼ö ÀÖ½À´Ï´Ù.
Á¤¸®ÇÏ¸é ¼Òȱ⳻°ú (³»½Ã°æÀÇ»ç)ÀÇ ÀÔÀå¿¡¼ ´Ù½Ã Çѹø ȯÀÚ¸¦ ÀÚ¼¼È÷ Æò°¡ÇÏ°í ÇÊ¿ä½Ã °¨¿°³»°ú ÀÇ»ç¿Í »óÀÇÇÏ´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù. Àúµµ °æÇèÀÌ ¾ø¾î¼ ´Ù¼Ò ¾Ö¸ÅÇÑ ´äº¯ÀÌ µÈ °Í °°½À´Ï´Ù.^^
[2016-9-21. °¨¿°³»°ú Á¶¼±¿µ ±³¼ö´Ô ´äº¯]
Àúµµ ¿¹¹æÀûÀ¸·Î fluconazoleÀ» Åõ¿©ÇÏ´Â °æ¿ì¸¦ º¸Áö´Â ¸øÇß½À´Ï´Ù. HIV ȯÀڵ鵵 Ç×¹ÙÀÌ·¯½ºÁ¦·Î Àß Á¶ÀýµÇ´Â °æ¿ì°¡ ´ëºÎºÐÀÌ¾î¼ symptomatic recurrent Candida esophagitis¸¦ °æÇèÇÏÁö ¸øÇß½À´Ï´Ù. ¾î¼¸é inhalation steroid¸¦ ¸¹ÀÌ »ç¿ëÇϽô ȣÈí±â ³»°ú ±³¼ö´ÔÀº °æÇèÀÌ ÀÖÀ¸½ÇÁö ¸ð¸£°Ú½À´Ï´Ù.
2³â »çÀÌ 13¹ø Àç¹ßÇß´Ù¸é ºÐ¸íÈ÷ ¾ÆÁÖ µå¹® °æ¿ìÀÔ´Ï´Ù. ÀÌ È¯ÀÚ°¡ oral fluconazole Ä¡·á ÈÄ ³»½Ã°æÀûÀ¸·Î È£ÀüµÈ °ÍÀ» È®ÀÎÇÑ ÀûÀÌ ÀÖ´ÂÁö, ¾àÁ¦ÀÇ ¿ë·® ¹× Ä¡·á±â°£µµ ±Ã±ÝÇÕ´Ï´Ù.
¶ÇÇÑ ´Ù¸¥ À§Çè¿ä¼Ò´Â ¾ø´ÂÁö È®ÀÎÀÌ ÇÊ¿äÇÒ °Í °°½À´Ï´Ù. HIV negative ȯÀÚ¿¡¼ recurrent esophagitis ÀÚ·á´Â °ÅÀÇ ¾ø°í ÃÊ·ÏÀ» Çϳª ã¾Ò½À´Ï´Ù. Èí¿¬/´ç´¢µµ À§Çè¿ä¼Ò´Â µÉ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ ÀæÀº Ç×»ýÁ¦ »ç¿ëµµ ¿øÀÎÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
°¡Àå ÃÖ±Ù¿¡ ³ª¿Â 2016³â °¡À̵å¶óÀÎ(Pappas PG. Clin Infect Dis 2016)Àº 2009³â °¡À̵å¶óÀÎÀÇ ¾÷µ¥ÀÌÆ®ÀÔ´Ï´Ù. À̹ø¿¡µµ 1ÁÖÀÏ¿¡ 3¹ø ¿ë¹ýÀÌ Àִµ¥ ("139. For patients who have recurrent esophagitis, chronic suppressive therapy with fluconazole, 100-200 mg 3 times weekly, is recommended (strong recommendation; high-quality evidence"), ±Ç°í¾ÈÀÇ ±Ù°Å´Â HIV ȯÀÚ¿¡¼ÀÇ randomizded study ÀÔ´Ï´Ù (2009³â°ú ´Ù¸¥ °ÍÀº ¾ø½À´Ï´Ù). HIV ȯÀÚÀÇ ±âȸ°¨¿° Ä¡·á¿¡ ´ëÇÏ¿© °¡À̵å¶óÀο¡´Â ¾Æ·¡¿Í °°ÀÌ ³ª¿Í ÀÖ½À´Ï´Ù.
A randomized clinical trial in HIV-infected patients with CD4 counts <150 cells/mm3 documented a significantly lower number of episodes of oropharyngeal candidiasis and other invasive fungal infections with continuous fluconazole therapy (3 times a week) compared with episodic fluconazole treatment for recurrences. This clinical trial also demonstrated no difference in the risk of developing clinically significant fluconazole resistance between the two groups among those receiving ART.
However, secondary prophylaxis (chronic suppressive therapy) is not recommended by most HIV specialists for recurrent oropharyngeal or vulvovaginal candidiasis unless patients have frequent or severe recurrences (BIII) because therapy for acute disease is effective, mortality associated with mucocutaneous disease is low, potential exists for drug interactions and for the development of antifungal-resistant Candida, and prophylaxis is costly.
³»¼ºÀÌ ´õ Áõ°¡µÇ´Â´Ù´Â Áõ°Å´Â ¾øÁö¸¸ »ó±â ÀÌÀ¯·Î HIV ȯÀÚ¿¡¼µµ ÃßõµÇÁö ¾Ê´Â´Ù´Â °ÍÀÔ´Ï´Ù.
°³ÀÎÀûÀÎ ÀÇ°ßÀ¸·Î´Â À§Çè¿ä¼Ò¿¡ ´ëÇÑ ÀçÆò°¡¿Í oral fluconazole 400mg 21ÀÏ Á¤µµ·Î ÃæºÐÈ÷ Ä¡·áÇÏ°í Ä¡·á ¹ÝÀÀÀ» È®½ÇÈ÷ Æò°¡ÇÏ´Â °ÍÀÌ ÁÁÀ» °Í °°½À´Ï´Ù. Refractory ÇÏ´Ù¸é ±×¿¡ ¸Â´Â Ä¡·á°¡ ÇÊ¿äÇÏ°Ú½À´Ï´Ù.
[2016-9-22. ÀÌÁØÇà comment]
À̹ø ÁúÀÇ ÀÀ´äÀ» ÅëÇÏ¿© ¸¹Àº °ÍÀ» ¹è¿ü½À´Ï´Ù. ½Åµ¿Çö ¼±»ý´ÔÀ» benchmarkÇÕ´Ï´Ù (LiverTODAY 009). Àúµµ ¹Ù»Û ºÐµéÀ» À§ÇÑ ´Ù¼¸ÁÙ ¿ä¾àÀ» ½á º¸¾Ò½À´Ï´Ù.
1) Fluconazole 7-10ÀÏ Åõ¿©·Î È£ÀüµÇÁö ¾Ê´Â Candida esophagitis°¡ ÀÖ½À´Ï´Ù. Ç×»ó ÃßÀû ³»½Ã°æÀÌ ÇÊ¿äÇÑ °ÍÀº ¾Æ´ÏÁö¸¸, Áõ»óÀÌ Áö¼ÓµÇ°Å³ª Àç¹ßµÇ´Â °æ¿ì´Â fluconazole Åõ¿© ÈÄ ³»½Ã°æ Àç°ËÀ¸·Î È£Àü ¿©ºÎ¸¦ È®ÀÎÇÏ´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù.
2) HIV¿¡ ´ëÇÑ Ç×¹ÙÀÌ·¯½º Ä¡·á°¡ ¹ßÀüÇÏ¸é¼ HIV¿¡ ÀÇÇÑ Candida esophagitis´Â Àß Ä¡·áµÇ°í ÀÖ½À´Ï´Ù. ¸é¿ª±â´ÉÀÌ È£ÀüµÇ¸é Candida esophagitisµµ È£ÀüµÇ±â ¶§¹®ÀÔ´Ï´Ù.
3) Fluconazole maintenance°¡ °¡À̵å¶óÀο¡ ¾ð±ÞµÇ°í ÀÖÁö¸¸, ½ÇÁ¦ ÀÓ»ó¿¡¼ »ç¿ëµÇ´Â ¿¹´Â °ÅÀÇ ¾ø½À´Ï´Ù. °¨¿° ³»°ú ¼±»ý´Ô ¿©·¯ºÐ¿¡°Ô È®ÀÎÇÑ ³»¿ëÀÔ´Ï´Ù.
4) Fluconazole maintenance¸¦ ÇÏÁö ¾Ê´Â ÀÌÀ¯ Áß Çϳª°¡ ÀúÇ×±ÕÁÖÀÇ ¹ß»ýÀÎ °ÍÀ¸·Î ¾Ë°í ÀÖ¾ú´Âµ¥, »ç½Ç ÀÌ¿¡ ´ëÇÑ ±Ù°Å´Â ºÎÁ·ÇÑ ¸ð¾çÀÔ´Ï´Ù.
5) ¹«Áõ»ó Candida esophagitis¿Í À¯Áõ»ó Candida esophagitis´Â È®½ÇÈ÷ ±¸ºÐÇÏ´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù. À̹ø ³íÀÇ´Â À¯Áõ»ó Candida esophagitis¿¡ ´ëÇÑ ³»¿ëÀ̾ú½À´Ï´Ù. ¹«Áõ»ó Candida esophagitis±îÁö extrapolationÇÏÁö ¸¶½Ã±â ¹Ù¶ø´Ï´Ù.
[2020-10-21. ¼ö´ÙÇü on-line talk show¿¡¼ ³ª¿Â Áú¹®µé]
1) 2016³â °¡À̵å¶óÀÎ: Pappas PG. Clin Infect Dis 2016
2) 2009³â °¡À̵å¶óÀÎ: Pappas PG. Clin Infect Dis 2009
3) Asymptomatic esophageal candidiasis in AIDS-related complex (Ann Intern Med 1986)
4) Options for the management of mucosal candidiasis in patients with AIDS and HIV infection (Pharmacotherapy 1999) - Candida esophagitis is also of concern, since it occurs in more than 10% of patients with AIDS.
4) The natural history of esophageal candidiasis after successful treatment in patients with AIDS (Gastroenterology 1994)
5) À§»ê¾ïÁ¦Á¦ Ä¡·á ÈÄ ¾ÇÈµÈ ½ÄµµÄµð´ÙÁõ ¹× È¿¸ð À§¼®À» µ¿¹ÝÇÑ À§Äµð´ÙÁõ ¹ß»ý 1¿¹ (³»°úÇÐȸÁö 2006)
6) EndoTODAY ÇÑ ¿¬¿¹ÀÎÀÇ ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ¿¡ ´ëÇÑ ´Ü»ó
7) ¹«Áõ»ó ½Äµµ ĵð´ÙÁõ YouTube °ÀÇ (ÀÌÁØÇà)
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.